Chikungunya Fever: The Roles of Integrative Medicine in the Post-vaccine Era
Future Integrative Medicine · 30.06.2026 · 000 (000) · 000-000
DOI: 10.14218/fim.2026.00011 ↗Kurz gefasst
Fachartikel in der Zeitschrift Future Integrative Medicine, online erschienen am 11.06.2026. Verfasst von Lanjing Zhang. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Chikungunya fever is becoming a major healthcare threat in more than 110 countries and may impact a total population of 2.8 billion, particularly those in East and Central Africa, South America, and Southeast Asia.1,2 VLA1553 (live-attenuated, single-dose, trade name IXCHIQ) and PXVX0317 (purified virus-like particles, trade name Vimkunya) are the two approved vaccines for Chikungunya virus (CHIKV).3-6 Their seroconversion rates were more than 95%, while their approval, accessibility, and indications differ across countries/regions.5,6 They thus will shift the paradigm
Zitieren
APA
Zhang, L. (2026). Chikungunya Fever: The Roles of Integrative Medicine in the Post-vaccine Era. Future Integrative Medicine, 000(000), 000-000. https://doi.org/10.14218/fim.2026.00011
Vancouver
Zhang L. Chikungunya Fever: The Roles of Integrative Medicine in the Post-vaccine Era. Future Integrative Medicine. 2026;000(000):000-000. doi:10.14218/fim.2026.00011
BibTeX
@article{Zhang2026,
author = {Zhang, Lanjing},
title = {Chikungunya Fever: The Roles of Integrative Medicine in the Post-vaccine Era},
journal = {Future Integrative Medicine},
year = {2026},
volume = {000},
number = {000},
pages = {000--000},
doi = {10.14218/fim.2026.00011}
}
EUVIMED